Tests tirzepatide added to ixekizumab for psoriasis and excess weight
Tests tirzepatide added to ixekizumab in adults with plaque psoriasis and excess weight.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Key facts
- Where
- Ann Arbor, Bellaire, Bellevue, Boardman, Bowling Green, Brighton, Caledonia, Cary, Columbia, Dallas, Douglasville, East Windsor, Fountain Valley, Fremont, Hialeah, Hoboken, Hollywood, Houston, Huntersville, Indianapolis, Layton, Los Angeles, New York, Northridge, Pflugerville, Phoenix, Plainfield, Plymouth Meeting, Portland, Portsmouth, Reno, Rockville, San Antonio, Smyrna, Tampa, Webster, and Wellington, United StatesSee the 38 sites
- Phase
- Phase 4
Where in United States
- David Fivenson, MD, PLCAnn Arbor, United StatesTaking people
- Bellaire Dermatology AssociatesBellaire, United StatesTaking people
- Bellevue Dermatology ClinicBellevue, United StatesTaking people
- Optima Research BoardmanBoardman, United StatesTaking people
- Equity Medical Bowling GreenBowling Green, United StatesTaking people
- Metro Boston Clinical PartnersBrighton, United StatesTaking people
- The Derm Institute of West MichiganCaledonia, United StatesTaking people
- Revival Research Institute, LLCCary, United StatesTaking people
- Columbia Dermatology & AestheticsColumbia, United StatesTaking people
- Modern Research Associates PllcDallas, United StatesTaking people
- Southeast Research SpecialistsDouglasville, United StatesTaking people
- Psoriasis Treatment Center of Central New JerseyEast Windsor, United StatesTaking people
- First Oc Dermatology Research IncFountain Valley, United StatesTaking people
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesTaking people
- NeoClinical ResearchHialeah, United StatesTaking people
- Care Access - HobokenHoboken, United StatesTaking people
- Encore Medical ResearchHollywood, United StatesTaking people
- Skin Care ResearchHollywood, United StatesTaking people
- Center for Clinical StudiesHouston, United StatesTaking people
- Onsite Clinical Solutions - HuntersvilleHuntersville, United StatesTaking people
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesTaking people
- Tanner ClinicLayton, United StatesTaking people
- Metropolis DermatologyLos Angeles, United StatesTaking people
- Equity MedicalNew York, United StatesTaking people
- Northridge Clinical TrialsNorthridge, United StatesTaking people
- Austin Institute for Clinical ResearchPflugerville, United StatesTaking people
- Medical Dermatology SpecialistsPhoenix, United StatesTaking people
- The Indiana Clinical Trials Center, PCPlainfield, United StatesTaking people
- Dermatology Associates of Plymouth MeetingPlymouth Meeting, United StatesTaking people
- Oregon Dermatology and Research CenterPortland, United StatesTaking people
- StracskinPortsmouth, United StatesTaking people
- Skin Cancer and Dermatology Institute - RenoReno, United StatesTaking people
- Dermatology and Skin Cancer Specialists, LLCRockville, United StatesTaking people
- Texas Dermatology and Laser SpecialistsSan Antonio, United StatesTaking people
- DelRicht Research - Thompson's StationSmyrna, United StatesTaking people
- MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical ResearchTampa, United StatesTaking people
- Center for Clinical StudiesWebster, United StatesTaking people
- TruDerm & TruSpaWellington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06857942
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.Read full original descriptionShow less
A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Inclusion: Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant); Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to <30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases); Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide; Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).
Exclusion: Have currently received ixekizumab for more than 4 months or less than 2 months; Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening; Have a known hypersensitivity to tirzepatide or to any of its component; Have a personal or family history of medullary thyroid cancer; Have type I diabetes mellitus; Have a history of chronic or acute pancreatitis at any time before screening (Visit 1); Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment; Have a history of ketoacidosis or hyperosmolar state/coma; Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting; Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide; Are currently enrolled in any other clinical study; Other exclusions; Have multiple endocrine neoplasia type 2.